Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD.

Mardinoglu A, Bjornson E, Zhang C, Klevstig M, Söderlund S, Ståhlman M, Adiels M, Hakkarainen A, Lundbom N, Kilicarslan M, Hallström BM, Lundbom J, Vergès B, Barrett PH, Watts GF, Serlie MJ, Nielsen J, Uhlén M, Smith U, Marschall HU, Taskinen MR, Boren J.

Mol Syst Biol. 2017 Mar 2;13(3):916. doi: 10.15252/msb.20167422.

2.

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Taskinen MR, Borén J.

Curr Atheroscler Rep. 2016 Oct;18(10):59. doi: 10.1007/s11883-016-0614-1. Review.

3.

The Contribution of GWAS Loci in Familial Dyslipidemias.

Ripatti P, Rämö JT, Söderlund S, Surakka I, Matikainen N, Pirinen M, Pajukanta P, Sarin AP, Service SK, Laurila PP, Ehnholm C, Salomaa V, Wilson RK, Palotie A, Freimer NB, Taskinen MR, Ripatti S.

PLoS Genet. 2016 May 26;12(5):e1006078. doi: 10.1371/journal.pgen.1006078. eCollection 2016 May.

4.

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.

Matikainen N, Björnson E, Söderlund S, Borén C, Eliasson B, Pietiläinen KH, Bogl LH, Hakkarainen A, Lundbom N, Rivellese A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR.

PLoS One. 2016 Jan 11;11(1):e0145890. doi: 10.1371/journal.pone.0145890. eCollection 2016.

5.

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans.

Adiels M, Mardinoglu A, Taskinen MR, Borén J.

Front Physiol. 2015 Nov 20;6:342. doi: 10.3389/fphys.2015.00342. eCollection 2015. Review.

6.

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models.

Berglund M, Adiels M, Taskinen MR, Borén J, Wennberg B.

PLoS One. 2015 Sep 30;10(9):e0138538. doi: 10.1371/journal.pone.0138538. eCollection 2015.

7.

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel..

Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. Epub 2015 May 25. Review.

8.

Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia.

Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Muñoz-Hernandez L, Cruz-Bautista I, Perez-Mendez O, Tusie-Luna MT, Gomez-Perez FJ, Pajukanta P, Matikainen N, Taskinen MR, Aguilar-Salinas CA.

BMC Endocr Disord. 2014 Nov 25;14:90. doi: 10.1186/1472-6823-14-90.

9.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia..

Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.

10.

Patients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals.

Lassenius MI, Mäkinen VP, Fogarty CL, Peräneva L, Jauhiainen M, Pussinen PJ, Taskinen MR, Kirveskari J, Vaarala O, Nieminen JK, Hörkkö S, Kangas AJ, Soininen P, Ala-Korpela M, Gordin D, Ahola AJ, Forsblom C, Groop PH, Lehto M.

Nutr Metab (Lond). 2014 Jun 13;11:28. doi: 10.1186/1743-7075-11-28. eCollection 2014.

11.

Amerindian-specific regions under positive selection harbour new lipid variants in Latinos.

Ko A, Cantor RM, Weissglas-Volkov D, Nikkola E, Reddy PM, Sinsheimer JS, Pasaniuc B, Brown R, Alvarez M, Rodriguez A, Rodriguez-Guillen R, Bautista IC, Arellano-Campos O, Muñoz-Hernández LL, Salomaa V, Kaprio J, Jula A, Jauhiainen M, Heliövaara M, Raitakari O, Lehtimäki T, Eriksson JG, Perola M, Lohmueller KE, Matikainen N, Taskinen MR, Rodriguez-Torres M, Riba L, Tusie-Luna T, Aguilar-Salinas CA, Pajukanta P.

Nat Commun. 2014 Jun 2;5:3983. doi: 10.1038/ncomms4983.

12.

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, Watts GF, Wiklund O; European Atherosclerosis Society Consensus Panel..

Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66. doi: 10.1016/S2213-8587(13)70191-8. Epub 2013 Dec 23. Review.

13.

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, Patel S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab. 2014 Jun;16(6):560-8. doi: 10.1111/dom.12281. Epub 2014 Mar 24.

14.

Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects.

Matikainen N, Burza MA, Romeo S, Hakkarainen A, Adiels M, Folkersen L, Eriksson P, Lundbom N, Ehrenborg E, Orho-Melander M, Taskinen MR, Borén J.

PLoS One. 2013 Nov 20;8(11):e79473. doi: 10.1371/journal.pone.0079473. eCollection 2013.

15.

Cardiac steatosis and left ventricular function in men with metabolic syndrome.

Nyman K, Granér M, Pentikäinen MO, Lundbom J, Hakkarainen A, Sirén R, Nieminen MS, Taskinen MR, Lundbom N, Lauerma K.

J Cardiovasc Magn Reson. 2013 Nov 14;15:103. doi: 10.1186/1532-429X-15-103.

16.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel..

Eur Heart J. 2013 Dec;34(45):3478-90a. doi: 10.1093/eurheartj/eht273. Epub 2013 Aug 15.

17.

Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci.

Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I, Arellano-Campos O, Muñoz-Hernandez LL, Gomez-Munguia L, Ordoñez-Sánchez ML, Reddy PM, Lusis AJ, Matikainen N, Taskinen MR, Riba L, Cantor RM, Sinsheimer JS, Tusie-Luna T, Pajukanta P.

J Med Genet. 2013 May;50(5):298-308. doi: 10.1136/jmedgenet-2012-101461. Epub 2013 Mar 15.

18.

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model.

Krengel A, Hauth J, Taskinen MR, Adiels M, Jirstrand M.

BMC Syst Biol. 2013 Jan 19;7:8. doi: 10.1186/1752-0509-7-8.

19.

Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis.

Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP, Kangas AJ, Soininen P, Savolainen MJ, Viikari J, Kähönen M, Perola M, Salomaa V, Raitakari O, Lehtimäki T, Taskinen MR, Järvelin MR, Ala-Korpela M, Palotie A, de Bakker PI.

PLoS Genet. 2012;8(8):e1002907. doi: 10.1371/journal.pgen.1002907. Epub 2012 Aug 16.

20.

Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.

Best JD, Drury PL, Davis TM, Taskinen MR, Kesäniemi YA, Scott R, Pardy C, Voysey M, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators..

Diabetes Care. 2012 May;35(5):1165-70. doi: 10.2337/dc11-1307. Epub 2012 Mar 19.

Supplemental Content

Loading ...
Support Center